Twenty years of experience helped prepare our INOmax Total Care® team for a year like no other

By working together with your critical care teams, INOmax Total Care was able to continue to help your NICU stay one step ahead during critical moments

The INOmax Total Care team continued to deliver in 20201*

*All stats are for 2020 through the month of September.

- CUSTOMER CARE SUPPORT HANDLED
  61,800 INBOUND AND OUTBOUND CALLS
- SCHEDULED ORDERS
  6207 EMERGENCY ORDERS
  6259 SCHEDULED ORDERS
- TOTAL ORDERS FULFILLED
  12,466
- EMERGENCY CONTRACTING
  6207
- ON-TIME DELIVERIES REMAINED ABOVE 99%
- CLINICAL SPECIALISTS TOOK
  1484 CALLS AND TRAINED NEARLY 7000 USERS
- CLINICAL NURSE EDUCATORS PROVIDED
  366 EDUCATIONAL PRESENTATIONS IN PERSON AND ONLINE
- CONTINUED DEDICATION TO EXPANDING GAS DELIVERY SYSTEM VALIDATIONS
  13 ADDITIONAL VALIDATIONS GAINED IN 2020
  BRINGING TOTAL TO >80 VALIDATIONS
- CYLINDER PRODUCTION
  64,780 CYLINDERS DELIVERED THAT’S AN AVERAGE OF 236 EVERY DAY

For more information on how INOmax Total Care helps support institutions and NICUs like yours, including emergency contracting for immediate support, visit inomax.com/totalcare

INDICATION
INOMAX® (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

SELECT IMPORTANT SAFETY INFORMATION
• INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.

Please see additional Important Safety Information on the next page and Full Prescribing Information.
INDICATION
INOMAX® (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION
• INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
• Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation.
• Methemoglobinemia and NO₂ levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
• In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.
• Monitor for PaO₂, inspired NO₂, and methemoglobin during INOMAX administration.
• INOMAX must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.


For more information about how INOmax Total Care helps institutions nationwide stay ahead of the next what-if, visit inomax.com/totalcare